Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the ...

Alvotech ALVO, a commercial-stage company developing and manufacturing biosimilar medicines for patients worldwide, is ...

Markets today await the Fed’s rate decision, key GDP data, and earnings from Meta, Microsoft, and Ford in a pivotal U.S.

Deckers Outdoor Corporation (DECK) delivered an impressive first-quarter fiscal 2026 performance, surpassing expectations and increasing year over year. The standout performances of its HOKA and UGG ...

Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025: ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

Therapeutics Market, valued at approximately USD 143.95 billion in 2023, is projected to witness strong expansion over the forecast period, reaching an estimated valuation exceeding USD 270 billion by ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

Oklahoma will blend the experience of Dolby and Daniels with talented youth further down the depth chart.